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Abstract: Objective and importance: Hodgkin-lymphoma (HL) is a well-curable disease. The
treatment usually includes combined multiagent conventional chemotherapy and
radiotherapy. Fifth of the patients need repeated treatments because of relapse or
primary progressive disease. Those HL patients, who cannot be cured at least with
salvage therapy (including autologous hemopoetic stem cell transplantation [auto-
HSCT]), have really unfavourable prognosis.
Intervention: For this heavily pretreated subset of HL patients, novel but less toxic
treatment strategies should be considered. Brentuximab-vedotin is a novel targeted
treatment option, which was administered after the failure of two different regimens in
patients, who were ineligible for auto - HSCT or after the failure of auto - HSCT.
Moreover, there are favourable data with chemotherapeutical regimens supplemented
with rituximab not only in relapsed but also in newly diagnosed classical HL patients.
Bendamustine, an almost forgotten 50-year-old drug lives its renessaince in the 21th
century, it can be administered in refractory HL as well. Combination of the "new" and
"old" drugs might be also helpful.
Conclusion: Our data suggest that rituximab plus bendamustin (supplemented with or
without brentuximab-vedotin) could be a suitable alternative bridging salvage therapy
for heavily pretreated HL patient.
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Case 1 (1.tiff) 
Figure 1. Stage IV relapse (A), Progression after 2 cycles of DHAP (B), CMR after 2 cycles of IGEV 
(C), Stage IV relapse on the post-Tx scan (D), Further progression without chemotherapy (E), Partial 
response after 2 cycles of RB (F), CMR after further 4 cycles of RB (G), Stage IV relapse (H), 
Progression after BV regimen (I), Progression after numerous palliative regimen (J). 
Case 1 (2.tiff) 
Figure 2. Stage IV relapse (A), Partial response after 2 cycles of DHAP (B), CMR after 2 cycles of 
IGEV (C), Stage II relapse after BV therapy (D), CMR after 6 cycles of RB (E), CMR without 
treatment (F), Stage II relapse (G), CMR after 2 cycles of RB (H). 
Case 3 (3.tiff) 
Figure 3. Primary staging PET/CT stage IV/BE (A), Interim PET/CT scan showed CMR after 2 cycles 
of ABVD (B), Restaging PET/CT after 6 cycles of ABVD and IFRT, the patient received CMR (C), 
Pulmonary laesions –  infection- (D), Stage IV relapse (E), Partial response after 2 cycles of DHAP 
(F), Progression after 4 cycles of DHAP (G), Partial response after 2 cycles of RB (H), Localized 
relapse after 6 cycles of RB (I), Progression after IFRT (J). 
Case 4 (4.tiff) 
Figure 4. Primary staging PET/CT stage II/BX (A), Interim PET/CT scan showed CMR after 
2 cycles of ABVD (B), Restaging PET/CT  scan showed progression after 6 cycles of ABVD 
(C), Further progression without chemotherapy (D), Progression after 2 cycles of DHAP (E), 
CMR after 2 cycles of RBBV (F), CMR on the post-Tx scan (G)  
Datasets
Introduction 
 
Thanks to risk- and response- adapted treatment strategies, more than 80% of newly 
diagnosed classical Hodgkin-lympoma (HL) patients can be cured, and are expected to be 
long-term survivors. HL remains a challenging disease in those patients, who progress or 
relapse after first-line therapy [1]. Salvage regimens (including auto-HSCT) can cure 
approximately 50% of relapsed/refractory patients. Auto-HSCT can be effective if it is 
performed in complete or very good partial remission. Those HL patients who cannot be 
cured at least with salvage therapy are expected to have a median survival of less than three 
years [2]. Treatment options have been quite limited for this subset of patients. The most 
promising new drugs (mTOR inhibitors, lenalidomide, histone deacetylase inhibitors, 
programmed death 1 [PD-1] blockers) are available only in clinical trials for the treatment of 
relapsed/refractory HL [3, 4]. It has been a great challenge to manage those HL patients who 
are waiting for auto- or allo-HSCT, but are not in complete remission. A suitable new option 
is anti-CD30 targeting with brentuximab-vedotin (BV), which was approved for the therapy 
of auto-HSCT failure or after failure of two regimens in patients who were not candidates for 
transplantation [5]. There are growing numbers of promising results with chemotherapeutical 
regimens supplemented with rituximab not only in relapsed but also in newly diagnosed 
classical HL patients [6, 7]. Moreover, there are favourable data with the application of a 
“new-old” drug called bendamustine [8, 9] Here we report on four heavily pretreated patients 
whose initial treatment failed. So far there have been no published data with rituximab–
bendamustine-brentuximab-vedotin therapy for the treatment of relapsed/refractory HL 
patients.  
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Case 1 
In March 2007, a 22- year - old female patient was diagnosed with nodular sclerosis (NS) 
subtype HL, stage II/AX. She was treated with 8 cycles of adriamycin, bleomycin, vincristine, 
dacarbasine combination (ABVD) and involved field radiation therapy (IFRT). Complete 
remission was verified with CT in January 2008. In April 2008, stage IV/B relapse was 
recognized, which was confirmed by PET/CT (Fig1A). After two cycles of salvage 
dexamethasone, cisplatinum, and cytosine arabinoside therapy (DHAP), the PET/CT showed 
progression (Fig1B), so the treatment was modified to ifosfamide, gemcitabine, vinorelbine, 
and prednisone (IGEV) regimen. The administration of two cycles of IGEV therapy resulted 
in complete metabolic remission (CMR) on the next PET/CT in July 2008 (Fig1C). In August 
2008, a successful CD34+ stem cell harvesting was performed. In October 2008, a rapid 
progression of the lymphoma was recognized, so total body irradiation was applied before the 
R-mini-BEAM (rituximab-carmustine-etoposide-cytosin-arabinosid-melphalan) conditioning. 
The auto-HSCT was performed on 18 October 2008. In March 2009, disseminated relapse 
was detected on the 100 days post-transplantation (post-Tx) PET/CT scan (Fig1D). However, 
as she was in a good clinical condition, no chemotherapy was given, but she was referred for 
an allo-HSCT, and in the lack of a human leukocyte antigen identical sibling, the search for 
an unrelated bone marrow donor was started. In December 2009, the control PET/CT scan 
showed further progression (Fig1E) therefore, ifosfamide, carboplatine, etoposide (ICE) 
rescue treatment was started, which was intolerable because of side effects (grade III-IV 
myelosuppression). In March 2010, bendamustine-based therapy with additional rituximab 
(RB) was initiated. The patient received a dose of bendamustine of 90 mg/m2 on the first and 
second days, and she received 375 mg/m2 rituximab on the first day of each 28-day cycle. 
After two cycles of this regimen, a partial treatment response was detected on the control 
PET/CT scan (Fig1F), and after four further cycles of the RB therapy, she achieved CMR 
(Fig1G). The patient was expected to undergo an allo-HSCT with reduced intensity 
conditioning (RIC) as she had only a matched unrelated donor. In February 2011, based on 
the control PET/CT scan a disseminated relapse was recognised (Fig1H), so we started an RB 
regimen, which had formerly been effective. After 2 cycles of RB therapy, B symptoms were 
recognised, so the treatment was modified to BV (1.8 mg/kg, every 3 week), as a 
monotherapy, which resulted in clinically stable disease. In February 2012, further 
progression appeared after 5 cycles of BV regimen (Fig1I). Numerous palliative 
chemotherapy regimens (included vinorelbine, dexamethasone, carboplatin) were ineffective 
(Fig1J) and she died on 01. November 2012. 
Case 2 
In October 2006, a 34-year-old male was diagnosed with NS subtype of HL, clinical stage 
III/B. After 6 cycles of ABVD chemotherapy he achieved complete remission, which was 
verified with CT. In September 2011, another lymph node biopsy was performed and the 
histological examination revealed lymphocyte rich (LR) subtype of HL, stage IV/BE (Fig2A). 
After 2 cycles of salvage DHAP therapy the PET/CT scan showed partial remission (Fig2B), 
so the treatment was modified IGEV. He was administered 2 cycles of IGEV regimen, and 
CMR was detected on the next PET/CT examination (Fig2C). In March 2012, he underwent 
an R-BEAM conditioning followed by auto-HSCT. Post-Tx maintenance therapy was started 
with BV (1.8 mg/kg). In April 2013, after the administration of 16 cycles of BV the control 
PET/CT scan revealed supradiaphragmatic relapse (Fig2D). In June 2013, RB (rituximab 
375mg/m2 on day 1; bendamustine 120 mg/m2 on days 1 and 2, each 28 day cycle) rescue 
therapy was started. After 6 cycles of RB, the next PET/CT examination detected CMR 
(Fig2E), and the patient was in CMR without chemotherapy in January 2014 (Fig2F). He was 
referred for an allo-HSCT, but he had only a matched unrelated donor. In September 2014, 
the control PET/CT evaluted relapse (Fig2G), so we started the RB immunochemoterapy 
again, which had formerly been effective. After 2 cycles of RB therapy the patient was in 
excellent clinical condition and the PET/CT also showed CMR (Fig2H). In the hope of 
maintaining a long-term CR, to additional cycles of RB therapy will be administered and the 
patient is expected to undergo a haploidentical allo-HSCT with reduced intensity 
conditioning.  
 
 
 
 
 
 
 
 
 
Case 3 
In August 2010, a 61-year-old male was diagnosed with stage IV/BE (Fig3A), LR subtype of 
HL. After administration of 2 cycles of ABVD, the interim PET/CT scan showed CMR 
(Fig3B). After 6 cycles of ABVD and IFRT (36Gy) the patient achieved CR, which was 
confirmed by PET/CT scan (Fig3C-3D). In November 2012, after 15 months of CR, B 
symptoms occurred, so the next PET/CT detected disseminated stage IV relapse (Fig3E). In 
January 2013, another biopsy sample was taken from a paraaortical lymph node. The 
histology revealed mixed cellularity subtype of HL, so DHAP salvage treatment was started. 
An auto-HSCT was planned, but the patient refused the procedure. After 2 cycles of DHAP 
therapy, the PET/CT detected partial response (Fig3F). In September 2013, after 4 complete 
courses of DHAP the PET/CT scan showed progression (Fig3G), therefore the therapy was 
changed into RB regimen (rituximab 375mg/m2 on day 1; bendamustine 120 mg/m2 on days 
1 and 2, each 28 day cycle), in October 2013. After the administration of 2 cycles of RB 
regimen, the next PET/CT scan revealed a partial response (Fig3H). A further 4 cycles of RB 
were given, and the next PET/CT detected a new hypermetabolic mass before the vertebrae 
XII (Fig3I). Because of the localized relapse, IFRT therapy (30Gy) was recommended. In 
September 2014, further progression was revealed on the control PET/CT (Fig3J). 
Considering these results, BV (1.8 mg/kg) plus ICE rescue treatment was started in November 
2014. In March 2015, after 2 cycles of BV-ICE regimen, a control PET/CT examination is 
planned. 
Case 4 
In January 2013, a 21-year-old male was diagnosed with stage II/BX (mediastinal bulky), NS 
subtype of HL (Fig4A). The interim PET/CT result was almost CMR after receiving 2 cycles 
of ABVD (Fig4B). In October 2013, after 6 complete courses of ABVD, the restaging 
PET/CT scan showed a residual mediastinal mass (Fig4C). IFRT therapy was recommended, 
but the patient refused it. Considering the patient’s good clinical condition, watchful waiting 
was chosen. In November 2013, the next PET/CT detected progression (Fig4D), so we 
planned mediastinal lymph node biopsy. Unfortunately, it was refused by the patient again. In 
January 2014, after 2 cycles of salvage DHAP regimen the next PET/CT verified further 
progression (Fig4E). Cervical lymph node biopsy confirmed NS subtype of HL. Considering 
this result, the treatment was modified into RBBV regimen (rituximab 375mg/m2 on day 1; 
bendamustine 120 mg/m2 on days 1 and 2, each 28 day cycle; 1.8 mg/kg brentuximab-vedotin 
on day 1). After the administration of 2 cycles of RBBV, the next PET/CT scan verified CMR 
(Fig 4F). After R-BEAM conditioning regimen, the patient underwent a successful auto-
HSCT, which was supplemented with mediastinal/neck/supraclavicular region IFRT (36 Gy). 
In September 2014, the post-Tx PET/CT examination detected CMR (Fig4G), BV 
maintenance treatment was started. In April 2015, based on physical examination, laboratory 
findings, and simple imaging procedures, the patient was still in CR.  
  
Discussion 
The management of classical HL relapse after a second-line treatment (including auto-HSCT) 
or primary refractory disease still remains a great challenge. In the case of a localized relapse 
IFRT might be effective [10]. Josting et al. reported that IFRT seemed to be most beneficial 
when recurrent disease extends beyond previously unirradiated lymph nodes in those patients 
who relapse after auto-HSCT (stage I-II relapse, without B symptoms and no extranodal 
disease) [11]. Radiotherapy as a salvage regimen could be suitable only limited portion of 
patients. Novel chemotherapeutical and/or targeted treatment strategies are needed to improve 
survival outcome. Blockade of the programmed death-1 (PD-1) pathway seems to be 
promising. Pembrolizumab and nivolumab are two anti-PD-1 antibodies, phase I clinical trials 
were evaluating the activity in relapsed /refractory HL. The overall response rates (ORR) 
were 53% and 87%. Inhibitors of histone deacetylase (HDACi: panobinostat, vorinostat 
entinostat, mocetinostat) shows favorable clinical activity with documented tumor reduction, 
but the ORR alone was between 16-27%. Lenalidomide, as a single agent has modest activity 
in heavily pretreated HL patients, the ORR was  between 13-19%. Based on the data above 
lenalidomide and HDACi, as single agents probably not effective enough in 
relapse/rectractory HL patients. Some new, phase I-II upcoming trials will investigate the 
anti-PD-1 antibodies, HDAC inhibitors, lenalidomide alone and in combination in heavily 
pretreated HL (which are available on the website http://clinicaltrials.gov). Related to the 
above mentioned results RB(BV) could be a suitable alternative salvage option for relapsed or 
primary refractory HL patients.   
 
Mechanism of action and the results of clinical trials 
1. Brentuximab vedotin 
BV is a targeted therapeutic option for HL patients. This drug provides significant 
improvement compared to conventional polychemotherapy. In 2012, Younes et al. reported 
favourable results of a large, phase II trial evaluating the activity of BV in heavily pretreated 
relapsing or refractory HL after auto-HSCT (BV dose was 1.8 mg/kg every 3 weeks) [12]. 
The overall response rate (ORR) was 75%, CR was seen in 34% of patients and PR in 40%. 
Currently running clinical trials are seeking the role of BV in a first-line setting, as well as 
treating autologous stem cell transplant candidate patients, relapsing after auto-HSCT, 
bridging to allogenic stem cell transplant and treating elderly patients [13]. There are a lot of 
open questions about its overall benefit and its combination possibilities with conventional 
chemotherapeutic agents, and if combination is possible which agent should be combined 
with it [4]. In addition, combination therapy may intensify side effects, in particular, 
combining with such agents, as bendamustine, which is also new in the treatment of HL.  
 
2. Bendamustine 
After BV, ”old” bendamustine is the second ”new” drug to enter clinical practice with 
promising efficacy in the past 30 years [14]. Bendamustine is a unique cytostatic agent with 
structural similarities to alkylating agents and purine analogues, but it is non-cross resistant 
with alkylating agents and other drugs either in vitro or in vivo [8]. Bendamustine is 
characterized by its bifunctional action, since it induces apoptosis due to its p53-dependent 
alkylating activity, with a DNA-damaging effect that is more pronounced and longer-lasting 
than that of other alkylating agents [15]. The definitive proof of activity came from four 
studies of single agent bendamustine in relapsed/refractory HL [16-19]. These studies also 
confirmed that bendamustine is a safe and effective regimen for patients relapsing after auto-
HSCT and an interesting cytoreductive strategy prior to allo-HSCT [14]. In 2013 Moskowitz 
et al. reported results of a phase II trial evaluating the activity of single agent bendamustine in 
heavily pre-treated patients. In 34 evaluable patients bendamustine was administered in a dose 
of 120 mg/m2 as a 30-min infusion on days 1 and 2 every 28 days. The ORR was 53%, CR 
was seen in 33% of patients and PR in 19%. In those HL patients who relapsed within 3 
months after auto-HSCT, no evaluable response was detected. The median duration of 
response was 5 months. The authors found these results unfavourable and speculated on the 
possibility of combining this treatment with other agents that might maintain the response 
duration [16]. Corazzelli et al. published retrospective data with single agent bendamustine in 
41 patients. After 2–4 cycles, ORR was 78% and CR was 29%. After 6-8 cycles of complete 
courses the final ORR was 58%, with 31% CR [17]. Other retrospective clinical trials [18, 19] 
confirmed these results. It would be useful to find the biological factors that identify the 
patients who are going to respond.  
 
 
3. Rituximab 
Rituximab is a monoclonal antibody directed against the cell-surface marker CD20. In a 
study, Rassidakis et al. reported classic HL Reed-Sternberg (HRS) cells expressed CD20 in 
22% of 598 patients studied [20]. Based on the new molecular and pathogenetical findings in 
Hodgkin lymphoma, it has become clear that the microenvironment plays a critical role in the 
survival of malignant HRS cells. HRS cells make up only approximately 1-5% of total tumor 
bulk in HL. It is thought that perhaps rituximab's effect in vivo may not be due to killing of 
HRS cells, rather it may be secondary to eliminating surrounding reactive B cells, leading to a 
decrease in cytokine and chemokine secretion, therefore targeted therapies against the 
microenvironmental CD20 positive polyclonal B cells and the putative HRS stem cells may 
increase the response rate and the survival of the HL patients. There are promising reports on 
the administration of rituximab in relapsed classical HL. In a study from M.D. Anderson 
Cancer Center, 22 heavily pre-treated HL patients (with CD20 expression on HRS cells) were 
enrolled. Rituximab was given IV weekly (375 mg/m2) for 6 consecutive weeks. The overall 
response rate was 22% (5 patients, 1 CR, 4 PR), and 36% (8 patients) had stable disease 
Objective response was seen regardless of CD20 expression on RS cells. [6]. A few case 
reports are available in the literature documenting the benefit of rituximab in HL [7] 
 
4. Combination therapy with R-B-BV 
Based on in vitro observations there is a synergism between bendamustine and rituximab [9]. 
Our data underline that bendamustine-rituximab treatment was an effective and very safe 
choice for heavily pre-treated patients [21]. Brentuximab vedotin and bendamustine have 
independent mechanisms of action and are highly active with manageable safety profiles 
when administered as single agents to patients with HL who relapse after auto-HSCT (BV: 
34% CR, bendamustine: 33% CR). Patients received 1.8 mg/kg BV on day 1 with 90mg/m2 
bendamustine on days 1 and 2 every 3-weeks for up to 6 cycles. Forty five patients (58% 
female), with median age of 35 years (range 19-79) were involved in the study. 58% of 
patients had relapsed disease and 42% of patients had primary refractory disease. The CR rate 
was 82% of patients and the overall objective response rate (CR+PR) was 94%. The majority 
of CRs were achieved after 2 cycles of combination therapy The average duration of response 
for patients who obtained CR was 10.4 months. Related the above mentioned and our results 
bendamustine (+R+/-BV) based salvage therapy might be helpful for this vulnerable HL 
population. [22]. Two patients achieved CR (Case1: 11 month and Case2: 15 month), one 
patient reached PR (Case3: 7 month) with RB regimen. RBBV treatment was successfully 
administered in one young refractory patient (Case4), who achieved complete remission after 
this novel treatment and underwent an auto-HSCT. The patient was in CR 17 month (April 
2014) ago. The RB(BV) therapy was a very safe regimen in our heavily pre-treated HL group, 
who relapsed or progressed after at least three lines of chemotherapy. The patients had no 
notable treatment-related side effects. There are no published data on trials with RB(BV) 
regimen, except our case report on RB therapy.  
 
Conclusion 
 
Rituximab - bendamustin (supplemented with brentuximab-vedotin) can be a less toxic and 
effective alternative bridging salvage option to achieve complete or good partial remission 
before auto/allo-HSCT for heavily pre-treated HL patients. Further clinical studies might be 
needed to clarify the correct place of this novel targeted treatment modality in 
relapsed/refractory HL populations. A combination with PD-1 checkpoint inhibitors might 
improve remission rates and expected sustained responses. 
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Dear Reviewer, 
 
Thank you  very much for the thorough revision of my manuscript. In the following, I would 
like to present my answers to your questions, as well as the corrections I made based on your 
suggestions.  
 
 
1. I have corrected the sentence in the “Discussion” section (paragraph 1, line 8).  
 
Radiotherapy as a salvage regimen could be suitable only for a limited portion of patients. 
Novel chemotherapeutical and/or targeted treatment strategies are needed to improve survival 
outcome. 
 
 
2-3. I have completed the data with toxicity, duration of response (from the start date of 
RB(BV) regimen) of each patients, and I have also expanded the sentences about feasibility 
and low toxicity of these regimens in the “Discussion” section.  
 
Two patients achieved CR (Case1: 11 month and Case2: 15 month), one patient reached PR 
(Case3: 7 month) with RB regimen. RBBV treatment was successfully administered in one 
young refractory patient (Case4), who achieved complete remission after this novel treatment, 
and underwent an auto-HSCT. The patient was in CR 17 month (April 2014) ago. The 
RB(BV) therapy was a very safe regimen in our heavily pre-treated HL group, who relapsed 
or progressed after at least three lines of chemotherapy. The patients had no notable 
treatment-related side effects. There are no published data on trials with RB(BV) regimen, 
except our case report on RB therapy.  
 
The text has been completed with the data above in the „Discussion” section, on 
„Combination therapy with R-B-BV” and in line 10. 
 
 
4. I have completed the data with the characteristics of the patients and duration of response. 
 
Forty five patients (58% female), with median age of 35 years (range 19-79) were involved in 
the study. 58% of patients had relapsed disease and 42% of patients had primary refractory 
disease. The CR rate was 82% of patients and the overall objective response rate (CR+PR) 
was 94%. Related the above mentioned and our results bendamustine (+R+/-BV) based 
salvage therapy might be helpful for this vulnerable HL population. The average duration of 
response for patients who obtained CR was 10.4 months. 
 
The text has been completed with the data above in the „Discussion” section, on 
„Combination therapy with R-B-BV” and in line 8. 
 
 
5. I have supplemented the text with the results of the new drugs, and comparison with our 
data.  
 
Blockade of the programmed death-1 (PD-1) pathway seems to be promising. Pembrolizumab 
and nivolumab are two anti-PD-1 antibodies, phase I clinical trials were evaluating the 
activity in relapsed /refractory HL. The overall response rates (ORR) were 53% and 87%.  
Response to reviewer comments
Inhibitors of histone deacetylase (HDACi: panobinostat, vorinostat entinostat, mocetinostat) 
shows favorable clinical activity with documented tumor reduction, but the ORR alone was 
between 16-27%. Lenalidomide, as a single agent has modest activity in heavily pretreated 
HL patients, the ORR was  between 13-19%. Based on the data above lenalidomide and 
HDACi, as single agents probably not effective enough in relapse/rectractory HL patients. 
Some new, phase I-II upcoming trials will investigate the anti-PD-1 antibodies, HDAC 
inhibitors, lenalidomide alone and in combination in heavily pretreated HL (which are 
available on the website http://clinicaltrials.gov). Related to the above mentioned results 
RB(BV) could be a suitable alternative salvage option for relapsed or primary refractory HL 
patients.   
 
The text has been completed with the data above in the „Discussion” section, on paragraph 1, 
and in line 9. 
 
6. I have corrected the brentuximab-vedotin dose from “mg/m2” to “mg/kg” in Case3 and 
Case4.  
 
7. I apologize for the grammatical errors, I have checked and corrected our mistakes again. 
 
Abstract 
 
Objective and importance: Hodgkin-lymphoma (HL) is a well-curable disease. The treatment usually 
includes combined multiagent conventional chemotherapy and radiotherapy. Fifth of the patients 
need repeated treatments because of relapse or primary progressive disease. Those HL patients, who 
cannot be cured at least with salvage therapy (including autologous hemopoetic stem cell 
transplantation [autoHSCT]), have really unfavourable prognosis. Intervention: For this heavily 
pretreated subset of HL patients, novel but less toxic treatment strategies should be considered. 
Brentuximab-vedotin is a novel targeted treatment option, which was administered after the failure 
of two different regimens in patients, who were ineligible for auto - HSCT or after the failure of auto - 
HSCT. Moreover, there are favourable data with chemotherapeutical regimens supplemented with 
rituximab not only in relapsed but also in newly diagnosed classical HL patients. Bendamustine, an 
almost forgotten 50-year-old drug lives its renessaince in the 21th century, it can be administered in 
refractory HL as well. Combination of the "new" and "old" drugs might be also helpful. Conclusion: 
Our data suggest that rituximab plus bendamustin (supplemented with or without brentuximab-
vedotin) could be a suitable alternative bridging salvage therapy for heavily pretreated HL patient. 
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Introduction 
Thanks to the risk- and response adapted treatment strategies, more than 80% of newly 
diagnosed classical HL patients can be cured, and they are expected to be long term survivors. 
HL remains a challenging disease in those patients, who progress or relapse after first line 
therapy [1]. Salvage regimens (including auto-HSCT) can be cure approximately 50% of 
relapsed/refractory patients. Auto-HSCT can be effective if it is performed in complete or 
very good partial remission. Those HL patients, who can not be cured at least with salvage 
therapy, are expected to have a median survival of less than three years [2]. Treatment options 
have been quite limited for this subset of patients. The most promising new drugs (mTOR 
inhibitors, lenalidomide, histone deacetylase inhibitors, programmed death 1 [PD-1] blockers) 
are available only in clinical trials for the treatment of relapsed/refractory HL [3, 4]. It has 
been a great challenge to manage those HL patients, who are waiting for auto- or allo-HSCT, 
but are not in complete remission. A suitable new option is anti-CD30 targeting with 
brentuximab vedotin (BV), which was approved for the therapy of the auto-HSCT failure or 
after failure of two regimens in patients who were not candidates for transplantation [5]. 
There are growing numbers of promising results with chemotherapeutical regimens 
supplemented with rituximab not only in relapsed but also in newly diagnosed classical HL 
patients [6, 7]. Moreover, there are favourable data with the application of a “new-old” drug 
called bendamustine (B) [8, 9] Here we report on four heavily pretreated patients who failed 
to the initial treatment. So far there have been no published data with rituximab–bendamustin-
brentuximab-vedotin therapy for the treatment of relapsed/refractory HL patient.
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Case1 
In March 2007, a 22-year-old female patient was diagnosed with nodular sclerosis (NS) 
subtype HL, stage II/AX. She was treated with 8 cycles of adriamycin, bleomycin, vincristine, 
dacarbasine combination(ABVD) and involved field irradiation therapy(IFRT). Complete 
remission was verified with CT in January 2008. In April 2008, stage IV/B relapse was 
recognized, which was confirmed by PET/CT (Fig1A). After two cycles of salvage 
dexamethasone-cisplatinum-cytosine/arabinoside(DHAP) therapy, the PET/CT showed 
progression (Fig1B), so the treatment was modified to ifosfamide-gemcitabine-vinorelbine-
prednisone(IGEV) regimen. The administration of two cycles IGEV therapy resulted in 
complete metabolic remission(CMR) on the next PET/CT, in July 2008 (Fig1C). In August 
2008, a successful CD34+ stem cell harvesting was performed. In October 2008, a rapid 
progression of the lymphoma was recognized, so total body irradiation was applied before the 
R-mini-BEAM (rituximab-carmustine-etoposide-cytosin/arabinosid-melphalan) conditioning. 
The auto-HSCT was performed on 18 October 2008. In March 2009, disseminated relapse 
was detected on the 100 days post‐transplantation (post-Tx) PET/CT scan (Fig1D). 
However, as she was in a good clinical condition, no chemotherapy was given, but she was 
referred for an allo-HSCT, and in the lack of a human leukocyte antigen‐identical sibling, 
search for an unrelated bone marrow donor was started. In December 2009, the control 
PET/CT scan showed further progression (Fig1E), therefore ifosfamide-carboplatine-
etoposide(ICE), rescue treatment was started, which was intolerable because of side effects 
(gradeIII-IV myelosuppression). In March 2010, bendamustine-based therapy with additional 
rituximab(RB) was indicated. The patient adopted dose of bendamustine was 90mg/m2 on the 
first and second days, and she received 375mg/m2 rituximab on the first day, each 28 day 
cycles. After two cycles of this regimen, a partial treatment response (PR) was detected on the 
control PET/CT scan (Fig1F), and after further four cycles of the RB therapy, she achieved 
CMR (Fig1G). The patient was expected to undergo an allo-HSCT with reduced intensity 
conditioning(RIC) as she has only a matched unrelated donor. In February 2011, based on the 
control PET/CT scan a disseminated relapse was recognised (Fig1H), so we started RB 
regimen, which was formerly effective. After 2 cycles of RB therapy, B symptoms were 
recognised, so the treatment was modified to BV (1.8mg/kg, every 3 week), as a 
monotherapy, which was resulted clinically stable disease. In February 2012, further 
progression was appeared after 5 cycles of BV regimen (Fig1I). Numerous palliative 
chemotherapy regimens (included vinorelbine, dexamethasone, carboplatin) were ineffective 
(Fig1J) and she was died on 01. November 2012.
Case2 
In October 2006, a 34–year-old male was diagnosed with NS subtype of HL, with III/B 
clinical stage. After 6 cycles of ABVD chemotherapy he achieved a complete remission, 
which was verified with CT. In September 2011, another lymph node biopsy was perfomed 
and the histological examination revealed lymphocyte rich (LR) subtype of HL, with stage 
IV/BE (Fig2A). After 2 cycles of salvage DHAP therapy the PET/CT scan showed PR 
(Fig2B), so the treatment was modified into IGEV. He was administered 2 cycles of IGEV 
regimen, and CMR was detected on the next PET/CT examination (Fig2C). In March 2012, 
he underwent an R-BEAM conditioning followed by auto-HSCT. Post-tx maintance therapy 
was started with BV(1.8mg/kg). In April 2013, after the administration of 16 cycles of BV the 
control PET/CT scan revealed supradiaphragmatic relapse (Fig2D). In June 2013, RB 
(rituximab 375mg/m2 on day 1; bendamustin 120mg/m2 on days 1 and 2, each 28 day cycle) 
rescue therapy was started. After 6 cycles of RB, the next PET/CT examination detected 
CMR (Fig2E), and the patient was in CMR without chemotherapy in January 2014 (Fig2F). 
He was referred for an allo-HSCT, but he had only a matched unrelated donor. In September 
2014, the control PET/CT evaluated relapse (Fig 2G), so we started the RB again, which was 
formerly effective. After 2 cycles of RB therapy the patient was in excellent clinical condition 
and the PET/CT showed also CMR (Fig 2H). In the hope of maintaining a long-term CR, two 
additional cycles of RB therapy will be administered and the patient is expected to undergo a 
haploidentical allo-HSCT with RIC.  
Case3 
In August 2010, a 61–year-old male was diagnosed with stage IV/BE (Fig3A), LR subtype of 
HL. After administration of 2 cycles of ABVD, the interim PET/CT scan showed CMR 
(Fig3B). After 6 cycles of ABVD and IFRT(36Gy) the patient achieved CR, which was 
confirmed by PET/CT scan (Fig3C-3D). In November 2012, after 15 month of CR B 
symptoms occurred, so the next PET/CT detected disseminated stage IV relapse (Fig 3E). In 
January 2013, another biopsy sample was taken from a paraaortical lymph node, the histology 
revealed mixed cellularity subtype of HL, so DHAP salvage treatment was started. An auto-
HSCT was planned, but the patient refused the procedure. After 2 cycles of DHAP therapy, 
the PET/CT detected PR (Fig3F). In September 2013, after 4 complete courses of DHAP the 
PET/CT scan showed progression (Fig 3G), therefore the therapy was changed into RB 
regimen (rituximab 375mg/m2 on day 1; bendamustin 120mg/m2 on days 1 and 2, each 28 
day cycle), in October 2013. After the administration of 2 cycles of RB regimen, the next 
PET/CT scan revealed a PR (Fig3H). Further 4 cycles of RB were given, and the next 
PET/CT detected a new hypermetabolic mass before the vertebrae XII (Fig3I), so because of 
the localized relapse IFRT therapy(30 Gy) was recommended. In September 2014 further 
progression was revealed on the control PET/CT (Fig3J). Considering these results, 
BV(1.8mg/m2) plus ICE rescue treatment was started in November 2014. In March 2015, 
after 2 cycles of BV-ICE regimen, a control PET/CT examination showed partial remission. 
Case4 
In January 2013, a 21–year-old male was diagnosed with stage II/BX, NS subtype of HL 
(Fig4A). The interim PET/CT result was almost CMR after receiving 2 cycles of ABVD 
(Fig4B). In October 2013, after 6 complete courses of ABVD, the restaging PET/CT scan 
showed a residual mediastinal mass (Fig4C). IFRT therapy was recommended, but the patient 
refused it. Considering the patient’s good clinical condition, watchful waiting was chosen. In 
November 2013, the next PET/CT detected progression (Fig4D), so we planned mediastinal 
lymph node biopsy, unfortunately it was refused by the patient again. In January 2014, after 2 
cycles of salvage DHAP regimen the next PET/CT verified further progression (Fig4E). 
Cervical lymph node biopsy confirmed NS subtype of HL. Considering this result, the 
treatment was modified into RBBV regimen (rituximab 375mg/m2 on day 1; bendamustin 
120mg/m2 on days 1 and 2, each 28 day cycle; 1.8 mg/m2 BV on day 1). After the 
administration of 2 cycles of RBBV, the next PET/CT scan verified CMR (Fig4F). After R-
BEAM conditioning regimen, he underwent a successful auto-HSCT, which was 
supplemented with mediastinal/neck/supraclavicular region IFRT(36Gy). In September 2014, 
the post-Tx PET/CT examination detected CMR (Fig4G), BV maintenance treatment was 
started. In April 2015, based on physical examination, laboratory findings, and simple 
imaging procedures, the patient was still in CR.  
Discussion 
The management of classical HL relapse after a second-line treatment (including auto-HSCT) 
or primary refractory disease still remain a great challenge. In case of a localized relapse 
IFRT might be effective [10]. Josting et al. reported that IFRT seemed to be most beneficial 
when recurrent disease extends beyond previously unirradiated lymph nodes in those patient 
who relapse after auto-HSCT (stage I-II relapse, without B symptoms and no extranodal 
disease) [11]. Radiotherapy, as a salvage regimen could be suitable only limited portion of 
patients, therefore novel chemotherapeutical and/or targeted treatment strategies are needed to 
improve survival outcome.  
 
Mechanism of action and the results of clinical trials 
1. Brentuximab-vedotin 
BV is a targeted therapeutic option for Hodgkin lymphoma patients. This drug provides 
significant improvement compared to conventional polychemotherapy. In 2012, Younes et al. 
reported favourable results of a large, phase II trial evaluating the activity of BV in heavily 
pretreated relapsing or refractory HL after auto – HSCT (BV dose was 1.8 mg/kg every 3 
weeks) [12]. The overall response rate (ORR) was 75%, CR was seen in 34% and PR in 40%. 
Currently running clinical trials are seeking for role of BV in the first line setting, as well as 
treating auto-HSCT candidate patients, relapsing after auto-HSCT, bridging to allogenic-
HSCT and treating elderly patients [13]. There are a lot of opened questions its overall benefit 
and its combination possibilities with conventional chemotherapeutic agents, and if so which 
agent should be combined with it [4]. In addition, combination therapy may intensify side 
effects, in particular, combining with such agents, like bendamustine, which is also new in the 
treatment of HL.  
 
2. Bendamustin 
After BV, ”old” bendamustin is the second ”new” drug to enter clinical practice with 
promising efficacy in the past 30 years [14]. Bendamustine is a unique cytostatic agent with 
structural similarities to alkylating agents and purine analogues, but it is non-cross resistant 
with alkylating agents and other drugs either in vitro or in vivo [8]. Bendamustine is 
characterized by its bifunctional action, since it induces apoptosis due to its p53-dependent 
alkylating activity, with a DNA-damaging effect that is more pronounced and longer-lasting 
than that of other alkylating agents [15]. The definitive proof of activity came from four 
studies of single agent bendamustine in relapsed/refractory HL [16-19]. These studies also 
confirmed that, the bendamustine is a safe and effective regimen for patients relapsing after 
auto-HSCT and an interesting cytoreductive strategy prior to allo-HSCT [14]. In 2013 
Moskowitz et al. reported results of a phase II trial evaluating the activity of single agent 
bendamustine in heavily pretreated patients. In 34 evaluable patient’s bendamustine was 
administered in a dose of 120 mg/m2, as a 30-min infusion on days 1 and 2 every 28 days. 
The ORR was 53%, CR was seen in 33% and PR in 19%. In those HL patients who relapsed 
within 3 months after auto-HSCT, no evaluable response was detected. The median duration 
of response was 5 month. The authors found these results is unfavourable and speculated on 
the possibility of combining this treatment with other agents that might maintain the response 
duration [16]. Corazzelli et al. published retrospective data with single agent bendamustin in 
41 patients. After 2–4 cycles, ORR was 78% and CR was 29%. After 6-8 cycles of complete 
courses the final ORR was 58%, with 31% CR [17]. Other retrospective clinical trials [18, 19] 
confirmed these results. It would be useful to find those biological factors that identify the 
patients who are going to respond.  
 
3. Rituximab 
Rituximab is a monoclonal antibody directed against the cell-surface marker CD20. In a 
study, Rassidakis et al. reported classic HL Reed-Sternberg (HRS) cells expressed CD20 in 
22% of 598 patients studied [20]. Based on the new molecular and pathogenetical findings in 
Hodgkin lymphoma, it has become clear that the microenvironment plays a critical role in the 
survival of the malignant HRS cells. HRS cells make up only approximately 1-5% of total 
tumor bulk in HL, it is thought that perhaps rituximab's effect in vivo may not be due to 
killing of HRS cells, rather may be secondary to eliminating surrounding reactive B cells, 
leading to a decrease in cytokine and chemokine secretion Therefore targeted therapies 
against the microenvironmental CD20 positive polyclonal B cells and the putative HRS stem 
cells may increase the response rate and the survival of the HL patients. There are promising 
reports on the administration of rituximab in relapsed classical HL. In a study from M.D. 
Anderson Cancer Center 22 heavily pretreated HL patients (with CD20 expression on HRS 
cells) were enrolled. Rituximab was given IV weekly (375 mg/m2) for 6 consecutive weeks. 
The overall response rate was 22% (5 patient, 1 CR, 4 PR), and 36% (8 patient) had stable 
disease Objective response was seen regardless of CD20 expression on RS cells. [6]. A few 
case reports are avaible in the literature documenting the benefit of rituximab in HL [7] 
 
4. Combination therapy with R-B-BV 
Based on in vitro observations there is a synergism between bendamustine and rituximab [9]. 
Our data underline that bendamustine-rituximab treatment was an effective and very safe 
choice for heavily pretreated patients [21]. BV and bendamustine have independent 
mechanisms of action and are highly active with manageable safety profiles when 
administered as single agents to patients with HL who relapse after auto-HSCT (BV:34% CR, 
bendamustine:33% CR). Patients received 1.8 mg/kg BV on day 1 with 90mg/m2 
bendamustine on days 1 and 2 every 3-week up to 6 cycles. The ORR was 94%, and the CR 
rate was 82%. The majority of CRs were achieved after 2 cycles of combination therapy. [22] 
Based on our experience, RB therapy was less toxic, but effective choice for this vulnerable 
HL population, who relapsed or progressed after at least three lines of chemotherapy, two 
patient achieved CR, one patient reached PR. RBBV treatment was successfully administered 
in one young refractory HL patient, who achieved complete remission after this novel 
treatment, and successfully underwent an auto – HSCT 
 
Conclusion 
 
Rituximab - bendamustin (supplemented with brentuximab-vedotin) can be a less toxic and 
effective alternative bridging salvage option to achieve complete or good partial remission 
before auto/allo - HSCT for heavily pretreated HL patient. Further clinical studies might be 
needed to clarify the correct place of this novel targeted treatment modality in 
relapsed/refractory HL population. A combination with PD-1 checkpoint inhibitors might 
improve remission rates and expected sustained response. 
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